Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 516-525

  Anthérieu, Sébastien ^a,b   Chesné, Christophe ^c   Li, Ruoya ^c   Camus, Sandrine ^c   Lahoz, Agustin ^d   Picazo, Laura ^d   Turpeinen, Miia ^f   Tolonen, Ari ^e   Uusitalo, Jouko ^e   Guguen Guillouzo, Christiane ^b,g   Guillouzo, André ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c BIOPREDIC   (France)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e Novamass Ltd   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DIMETHYL SULFOXIDE; MESSENGER RNA; OMEPRAZOLE; PHENOBARBITAL; RIFAMPICIN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; STABLE EXPRESSION; XENOBIOTIC METABOLISM;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; GENE EXPRESSION REGULATION; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HEPATOCYTES; HUMANS; ISOENZYMES; MEMBRANE TRANSPORT PROTEINS; OMEPRAZOLE; PHENOBARBITAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS; RIFAMPIN; RNA, MESSENGER; TIME FACTORS; XENOBIOTICS;

EID: 76749107104     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030197     Document Type: Article

References (34)

1. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.
2. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, and Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957-967.
3. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
4. FDA-Guide (2001) Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (CVM), Rockville, MD.
5. Girault I, Rougier N, Chesné C, Lidereau R, Beaune P, Bieche I, and de Waziers I (2005) Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 33:1803-1810.
6. Gómez-Lechón MJ, Donato MT, Castell JV, and Jover R (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 5:443-462.
7. Goyak KM, Johnson MC, Strom SC, and Omiecinski CJ (2008) Expression profiling of interindividual variability following xenobiotic exposures in primary human hepatocyte cultures. Toxicol Appl Pharmacol 231:216-224.
8. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99:15655-15660.
9. Guguen-Guillouzo C, Campion JP, Brissot P, Glaise D, Launois B, Bourel M, and Guillouzo A (1982) High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol Int Rep 6:625-628.
10. Guillouzo A (1998) Liver cell models in in vitro toxicology. Environ Health Perspect 106 (Suppl 2):511-532.
11. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, and Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66-73.
12. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
13. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, and Fardel O (2006) Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756-1763.
14. Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, and Guillouzo A (2008) Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 36:1111-1118.
15. Kanebratt KP and Andersson TB (2008a) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452.
16. Kanebratt KP and Andersson TB (2008b) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.
17. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, and Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651-2658.
18. Ko JW, Sukhova N, Thacker D, Chen P, and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862.
19. Lahoz A, Donato MT, Castell JV, and Gómez-Lechón MJ (2008a) Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr Drug Metab 9:12-19.
20. Lahoz A, Donato MT, Picazo L, Castell JV, and Gómez-Lechón MJ (2008b) Assessment of cytochrome P450 induction in human hepatocytes using the cocktail strategy plus liquid chromatography tandem mass spectrometry. Drug Metab Lett 2:205-209.
21. Lambert CB, Spire C, Claude N, and Guillouzo A (2009) Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234:345-360.
22. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, and Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
23. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
24. Moncion A, Truong NT, Garrone A, Beaune P, Barouki R, and De Waziers I (2002) Identification of a 16-nucleotide sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin. J Biol Chem 277:45904-45910.
25. Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, and Guillouzo A (1990) Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 191:437-444.
26. Morel F, Fardel O, Meyer DJ, Langouet S, Gilmore KS, Meunier B, Tu CP, Kensler TW, Ketterer B, and Guillouzo A (1993) Preferential increase of glutathione S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res 53:231-234.
27. Nishimura M, Koeda A, Shimizu T, Nakayama M, Satoh T, Narimatsu S, and Naito S (2008) Comparison of inducibility of sulfotransferase and UDP-glucuronosyltransferase mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Drug Metab Pharmacokinet 23:45-53.
28. Park GR and Miller E (1996) What changes drug metabolism in critically ill patients-III? Effect of pre-existing disease on the metabolism of midazolam. Anaesthesia 51:431-434.
29. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
30. Soars MG, Petullo DM, Eckstein JA, Kasper SC, and Wrighton SA (2004) An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32:140-148.
31. Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, and Pelkonen O (2007) In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 42:960-966.
32. Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, and Pelkonen O (2009) Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 23:748-753.
33. Turpeinen M, Uusitalo J, Jouko U, Jalonen J, Jorma J, Pelkonen O, and Olavi P (2005) Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123-132.
34. Zhou H, Tong Z, and McLeod JF (2004) "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44:120-134.